NCT07466901 2026-03-12
A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer
Fudan University
Phase NA Not yet recruiting
Clinical Trials
27 trialsNCT07432087 2026-02-25
Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 3 Not yet recruiting
NCT07400094 2026-02-10
NeoCamre-HN
National Medical Research Radiological Centre of the Ministry of Health of Russia
Phase 2 Not yet recruiting
NCT07314372 2026-01-20
FAD-HCC-001
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Not yet recruiting
NCT07324473 2026-01-07
Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study
First Affiliated Hospital of Chongqing Medical University
Phase 2 Not yet recruiting
NCT07309419 2025-12-30
Cocktail-001
Shanghai Zhongshan Hospital
Phase 2/3 Not yet recruiting
NCT07266350 2025-12-05
A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer
Chongqing University Cancer Hospital
Not yet recruiting
NCT07143292 2025-11-18
A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT07191977 2025-09-25
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma
West China Hospital
Phase 2 Not yet recruiting
NCT07159217 2025-09-08
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT06632405 2025-03-26
A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT06849492 2025-02-27
SHIFT-001
Fudan University
Phase 2 Not yet recruiting
NCT06759090 2025-01-06
Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer
Zhejiang University
Phase 2 Not yet recruiting
NCT06731153 2024-12-12
JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
Fudan University
Phase 2 Not yet recruiting
NCT06694324 2024-11-19
First-line Treatment of Advanced/unresectable DDLPS
Fudan University
Phase 2 Not yet recruiting
NCT06692491 2024-11-18
SPRING
Peking University Shenzhen Hospital
Phase 2 Not yet recruiting
NCT06632522 2024-10-09
Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients .
Beijing Tsinghua Chang Gung Hospital
Phase 2 Not yet recruiting
NCT06546280 2024-08-09
A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation
Zhujiang Hospital
Phase 2 Not yet recruiting
NCT06423937 2024-05-21
Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer
Fudan University
Phase 2 Not yet recruiting
NCT06335355 2024-03-28
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
Shanghai Shengdi Pharmaceutical Co., Ltd
Phase 2/3 Not yet recruiting
NCT06304545 2024-03-12
Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab
Harbin Medical University
Phase 2 Not yet recruiting
NCT06276933 2024-02-26
A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Tongji University
Phase 4 Not yet recruiting
NCT06010212 2023-08-24
Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2 Not yet recruiting
NCT05821452 2023-04-20
Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma
Fujian Medical University Union Hospital
Phase 2 Not yet recruiting
NCT05610332 2022-11-09
Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
Fujian Medical University
Phase 3 Not yet recruiting
NCT05524974 2022-09-01
Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes
Fujian Medical University
Phase 2 Not yet recruiting
NCT04616040 2020-11-04
A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer
Peking University
Not yet recruiting